Methotrexate-Based Drug Delivery Systems: Advances in Disease Treatment

Dear Colleagues,

Methotrexate (MTX) is a well-established drug for the treatment of a wide range of disease conditions such as cancer, psoriasis, and rheumatoid arthritis. Despite its well-established efficacy profile, MTX presents low permeability and solubility, which limits its absorption, being a constant target for pharmaceutical formulators engaging in new proposals of active pharmaceutical ingredient (API) solid-state variations and/or drug delivery system (DDS) platforms development, based on nanotechnology, smart polymers, controlled release, or alternative routes of administration to improve MTX bioavailability, reduce adverse effects, and maximize clinical efficacy, compared with conventional dosage forms. From an economic perspective, these DDS strategies can offer new attributes for improving MTX’s drug products efficacy, giving new opportunities for product lifecycle management, innovation, and patents, while they open up new venues for quality-of-life and well-being improvements in patients.

We are pleased to invite all researchers to submit their findings and recent advances on drug delivery platforms focused on methotrexate delivery.

This Special Issue aims to collect up-to-date formulation and targeting approaches for MTX, such as controlled release carriers, multiparticulate and nanotechnology-based systems, polymorphism, alternative routes of administration for the common goal of improving bioavailability, reduce adverse effects, and maximize clinical efficacy.

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, preformulation and formulation studies, pharmaceutical development, pharmaceutical compounding, physico-chemical characterization, and in vitro, preclinical, and clinical studies.

We look forward to receiving your contributions.

Dr. Flávia Chiva Carvalho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• drug delivery systems
• nanoparticles
• API solid-state
• methotrexate
• chemotherapy
• rheumatoid arthritis
• psoriasis